Global News

Sanofi in research collaboration with BWH for type 1 diabetes

Thursday, July 19, 2012 02:23 PM

Sanofi has announced a new research collaboration with Boston’s Brigham and Women's Hospital (BWH), a teaching and research affiliate of Harvard Medical School, focused on immunology of type 1 diabetes. The two organizations will share knowledge and apply their respective expertise in basic and applied research regarding diabetes and drug target and candidate development.

More... »

Panel reports first global harmonized protocol to measure key brain region tied to memory

Thursday, July 19, 2012 01:25 PM

An international panel of experts has developed the first global harmonized protocol for measuring a key region of the brain tied to memory, according to research reported at the Alzheimer's Association International Conference 2012 in Vancouver.

More... »

Grifols initiates safety study of inhaled alpha1-proteinase inhibitor for CF

Thursday, July 19, 2012 01:18 PM

Grifols, a global healthcare company based in Barcelona, Spain, plans to initiate a safety trial of a novel, inhaled formulation of alpha1-proteinase inhibitor [human] later this year.  In April, the FDA granted orphan drug designation for Grifols' inhaled alpha1 formulation as a treatment for cystic fibrosis, an inherited disease that can cause life-threatening lung infections. Orphan drug designation is granted to encourage the development of treatments that prevent, diagnose or treat rare diseases that affect fewer than 200,000 people per year in the U.S.

More... »

Clinipace Worldwide to manage Prometheus oncology program

Wednesday, July 18, 2012 01:29 PM

Morrisville, N.C.-based Clinipace Worldwide, a global digital research organization (dCRO), said Prometheus Laboratories, a specialty pharmaceutical and diagnostic company, has awarded it an Oncology Program.  Immediate plans are commencing for two metastatic melanoma studies.  

More... »

Alzheimer's treatment study reports three years with no decline in memory and function

Wednesday, July 18, 2012 01:23 PM

The first report of long-term (three-year) stabilization of Alzheimer's disease symptoms with IVIG, including no decline on measures of cognition, memory, daily functioning and mood, was reported at the Alzheimer's Association International Conference 2012 (AAIC 2012) in Vancouver.

More... »

Synexus expands presence in South Africa

Wednesday, July 18, 2012 01:21 PM

Synexus has further expanded its global presence with the opening of a new in-patient facility in Pretoria, South Africa. Synexus now has a total of four sites in South Africa, which provide access to millions of patients.

More... »

Clinical trials clarify role of exercise in cognitive function and dementia

Monday, July 16, 2012 10:59 AM

Four studies reported at the Alzheimer's Association International Conference 2012 describe the ability of targeted exercise training to promote improved mental functioning and reduced risk for cognitive impairment and dementia in cognitively healthy older adults and those with mild cognitive impairment (MCI).

More... »

GSK to acquire Human Genome Sciences for $14.25 per share in cash

Monday, July 16, 2012 10:51 AM

GlaxoSmithKline and Human Genome Sciences have announced a definitive agreement under which GSK will acquire HGS for $14.25 per share in cash.

More... »

AstraZeneca acquires neuroscience assets from Link Medicine

Friday, July 13, 2012 03:20 PM

AstraZeneca has acquired a portfolio of neuroscience assets from Link Medicine, a privately held biopharmaceutical company based in Massachusetts. Link Medicine has focused its R&D efforts in the field of autophagy, an intracellular process that clears and recycles misfolded proteins, and has been developing potential new treatments for a range of neurodegenerative diseases.

More... »

Quintiles launches Allume support services

Friday, July 13, 2012 03:19 PM

Quintiles has introduced Allume, a comprehensive go-to-market service to help biopharmaceutical companies efficiently launch new products and shorten timelines to peak sales, while retaining strategic and corporate control of their assets. Allume simplifies and organizes the complex and resource-intensive launch planning process, provides unique data-driven insights from market-entry experience across the globe and taps Quintiles’ local market and therapeutic category expertise.

More... »